Adriano Lazzarin

1985–2025 年に発表

117
論文数
21,059
被引用数
86
h 指数
116
i10 指数

被引用数

Adriano Lazzarin の年別被引用数1986 年: 被引用 1 件1987 年: 被引用 5 件1988 年: 被引用 7 件1989 年: 被引用 7 件1990 年: 被引用 7 件1991 年: 被引用 14 件1992 年: 被引用 27 件1993 年: 被引用 20 件1994 年: 被引用 23 件1995 年: 被引用 28 件1996 年: 被引用 29 件1997 年: 被引用 67 件1998 年: 被引用 73 件1999 年: 被引用 86 件2000 年: 被引用 89 件2001 年: 被引用 101 件2002 年: 被引用 91 件2003 年: 被引用 81 件2004 年: 被引用 131 件2005 年: 被引用 120 件2006 年: 被引用 125 件2007 年: 被引用 134 件2008 年: 被引用 202 件2009 年: 被引用 246 件2010 年: 被引用 176 件2011 年: 被引用 180 件2012 年: 被引用 163 件2013 年: 被引用 164 件2014 年: 被引用 97 件2015 年: 被引用 101 件2016 年: 被引用 101 件2017 年: 被引用 60 件2018 年: 被引用 67 件2019 年: 被引用 308 件2020 年: 被引用 358 件2021 年: 被引用 391 件2022 年: 被引用 242 件2023 年: 被引用 155 件2024 年: 被引用 193 件2025 年: 被引用 58 件2026 年: 被引用 2 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,805 件、この内訳の 28.9%イギリス: 引用元論文 517 件、この内訳の 8.3%イタリア: 引用元論文 473 件、この内訳の 7.6%フランス: 引用元論文 343 件、この内訳の 5.5%スペイン: 引用元論文 317 件、この内訳の 5.1%ドイツ: 引用元論文 242 件、この内訳の 3.9%カナダ: 引用元論文 204 件、この内訳の 3.3%スイス: 引用元論文 177 件、この内訳の 2.8%オーストラリア: 引用元論文 155 件、この内訳の 2.5%中国: 引用元論文 152 件、この内訳の 2.4%ベルギー: 引用元論文 136 件、この内訳の 2.2%南アフリカ: 引用元論文 136 件、この内訳の 2.2%
0%28.9%その他 25.3%

分野

  • Medicine69.7%
  • Immunology and Microbiology22.8%
  • Biochemistry, Genetics and Molecular Biology2.7%
  • Health Professions1.3%
  • Neuroscience1%
  • Computer Science0.4%
  • その他2.1%

トピック

  • HIV Research and Treatment14.5%
  • HIV/AIDS drug development and treatment12.7%
  • HIV/AIDS Research and Interventions10.1%
  • HIV-related health complications and treatments7.2%
  • Hepatitis C virus research2.3%
  • Immune Cell Function and Interaction2.2%
  • その他51%

共著者

全論文

検索で開く
  1. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    著者: , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 380

  2. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

    著者: , , , , , , , , , , , , , , - EClinicalMedicine 2023 被引用: 85

  3. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Finlayson, Anthony D. Kelleher, Kenneth Koh, David Lewis, James McMahon, Richard Moore, Norman Roth, Matt Shields, Stéphane De Wit, Éric Florence, Jean‐Christophe Goffard, Rémy Demeester, Patrick Lacor, Bernard Vandercam, Linos Vandekerckhove, Jonathan B. Angel, Jean‐Guy Baril, Brian Conway, Alexandra de Pokomandy, Jason Szabo, Sharon Walmsley, Olivier Bouchaud, Christian Chidiac, Pierre Delobel, Cécile Goujard, Christine Katlama, Jean‐Michel Molina, Gilles Pialoux, Patrick Philibert, Johannes R. Bogner, Stefan Esser, Ivanka Krznaric, Clara Lehmann, Christoph D. Spinner, Hans‐Jürgen Stellbrink, Christoph Stephan, Albrecht Stoehr, Enrico Barchi, Pietro Caramello, Francesco Castelli, Anna Maria Cattelan, Antonella D'Arminio Monforte, Antonio Di Biagio, Giovanni Di Perri, Andrea Gori, Franco Maggiolo, Barbara Menzaghi, Guglielmo Marco Migliorino, Cristina Mussini, Giovanni Penco, Massimo Puoti, Giuliano Rizzardini, Roberto Gulminetti, Adriano Lazzarin, Tiziano Quirino, Laura Sighinolfi, Pierluigi Viale, Gerardo Amaya Tapia, Jaime Andrade‐Villanueva, Enrique R Granados Reyes, Alma Perez Rios, Mario Santoscoy Gomez, Jan den Hollander, Bart Rijnders, José A. Hidalgo, Luis Hercilla Vásquez, Luis Ricardo Illescas, Anita Olczak, Kamal Mansinho, Patrícia Pacheco ほか 109 名 - The Lancet 2018 被引用: 381

  4. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valentina Canti, Jacopo Castellani, Barbara Castiglioni, Giulio Cavalli, Ludovica Cavallo, Massimo Cernuschi, Matteo Chiurlo, Marta Cilla, Elena Cinel, Paola Cinque, Caterina Conte, Valentina Da Prat, Anna Danise, Rebecca De Lorenzo, Antonio Dell’Acqua, Raffaele Dell’Acqua, Emanuel Della‐Torre, Liviana Della Torre, Gaetano Di Terlizzi, Iulia Dumea, Federica Farolfi, Marica Ferrante, Claudia Frangi, Luca Fumagalli, Gabriele Gallina, Bruno Germinario, Nicola Gianotti, Monica Guffanti, Hamid Hasson, Francesca Lalla, Marco Lanzillotta, Raffaele Li Voti, Emanuela Messina, Chiara Molinari, Elena Moizo, Marco Montagna, Giulia Morsica, Silvia Nozza, Maria Paola Pascali, Alessandro Patrizi, Marina Pieri, Antonella Poloniato, Dario Prestifilippo, Giuseppe A. Ramirez, Martina Ranzenigo, Jacopo Sapienza, F. Seghi, Giuseppe Tambussi, Chiara Tassan Din, Stefano Turi, Caterina Uberti‐Foppa, Concetta Vinci - Clinical Microbiology and Infection 2020 被引用: 388

  5. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey H. Burack, Thomas L. Campbell, Michelle Cespedes, Amanda Clarke, Megan Coleman, J Coll, Manuel Crespo Casal, Catherine Creticos, Gordon Crofoot, Frederick Cruickshank, Éric Cua, Eric S. Daar, Joseph de Wet, Edwin DeJesus, Jorge Del Romero Guerrero, William D. Dinges, Susanne Doblecki‐Lewis, Taylor Donovan, Olamide Dosekun, Jason Flamm, Joel E. Gallant, Jan Gerstoft, Richard Gilson, Jay Gladstein, Robert M. Grant, Robert Grossberg, Bernhard Haas, Jason Halperin, William D. Hardy, C. Bradley Hare, Shawn Hassler, Richard L. Hengel, William Henry, Theo Hodge, Sybil Hosek, Chris Hurt, Michelle Iandiorio, Heiko Jessen, Stephen Kegg, Gabriele Knecht, Gitte Kronborg, Ivanka Krznaric, Anthony LaMarca, Carsten Schade Larsen, Olav Larsen, Adriano Lazzarin, Clifford Leen, Christopher Lucasti, Patrick Mallon, Sharon Mannheimer, Martin Markowitz, Claudia Martorell, Kenneth Mayer, Anthony Mills, Jean‐Michel Molina, Sheldon Morris, Karam Mounzer, Nneka Nwokolo, Onyema Ogbuagu, Olayemi Osiyemi, Andrew E. Petroll, Patrick Philibert, John Phoenix, G. Pialoux, Daniel Podzamczer, Frank A. Post, Maria Prins, Moti Ramgopal, Bruce Rashbaum, Iain Reeves ほか 23 名 - The Lancet HIV 2021 被引用: 91

  6. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

    著者: , , , , , , , , , - The Lancet HIV 2015 被引用: 223

  7. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marianna Menozzi, Andrea Antinori, Roberta Gagliardini, Stefano Bonora, Micol Ferrara, Maurizio Zazzi, Maria Mercedes Santoro, Giulio Maria Corbelli, Maurizio Zazzi, Maria Mercedes Santoro, Andrea Galli, Elisabetta Carini, Maria Rita Parisi, Laura Galli, Andrea Poli, Alba Bigoloni, Marcello Tavio, Luca Butini, Andrea Giacometti, Emanuela Vaccher, Ferdinando Martellotta, Valentina Da Ros, Gioacchino Angarano, Annalisa Saracino, Flavia Balena, Franco Maggiolo, Laura Comi, Elisa Di Filippo, Daniela Valenti, Claudia Suardi, Barbara Mazzola, Pierluigi Viale, Leonardo Calza, Elena Rosselli Del Turco, Marta Vacas Ramirez, Francesco Castelli, Emanuele Focà, Anna Celotti, Francesca Brognoli, G. Bonoldi, Barbara Menzaghi, C Abeli, Maddalena Farinazzo, Francesco Ortu, Marco Campus, Bruno Cacopardo, Maurizio Celesia, Angelo Pan, Chiara Fornabaio, Alessandro Bartoloni, Gaetana Sterrantino, Francesca Rinaldi, Susanna Giachè, Blanc Pierluigi, Francesca Vichi, Francesco Maria Fusco, Teresa Santantonio, Sergio Ferrara, Serena Rita Bruno, Giovanni Cassola, Giovanni Cenderello, Marcello Feasi, Francesca Calautti, Matteo Bassetti, Antonio Di Biagio, Bianca Bruzzone, Stefania Artioli, Adriano Lazzarin, Antonella Castagna, Nicola Gianotti ほか 82 名 - Open Forum Infectious Diseases 2020 被引用: 51

  8. Dolutegravir in antiretroviral-naive adults with HIV-1

    著者: , , , , , , , , , - AIDS 2013 被引用: 163

  9. Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non–COVID-19 Controls

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2020 被引用: 109

  10. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , MANUEL C. IGLESIAS, Nathan Clumeck, Brian Conway, E DeJesus, Jean L. Delassus, P. de Truchis, Giovanni Di Perri, Massimo Di Pietro, Joan Duggan, Claudine Duvivier, Richard Elion, Joseph Eron, Douglas N. Fish, Joseph Gathe, Richard Haubrich, Heather Henderson, Charles B. Hicks, Laurent Hocqueloux, Sally Hodder, CB Hsiao, Christine Katlama, Michael J. Kozal, Princy Kumar, Sujata N. Lalla-Reddy, Adriano Lazzarin, F Leoncini, Josep M. Llibre, Kamal Mansinho, Philippe Morlat, Karam Mounzer, M. Murphy, C. Newman, Thuy Nguyen, Bacel Nseir, Patrick Philibert, Gilles Pialoux, Isabelle Poizot‐Martin, Moti Ramgopal, Gary Richmond, Dominique Salmon Ceron, Paul E. Sax, A. Scarsella, Michael Sension, Peter Shalit, L Sighinolfi, Louis Sloan, Catherine B. Small, David Stein, K. Tashima, Pablo Tebas, Carlo Torti, Marc Tribble, Didier Troisvallets, Christos Tsoukas, Pompeyo Viciana Fernandez, Derek Ward, Darrell P. Wheeler, Timothy Wilkin, Guy-Patrick Yeni, J. Louise Martin-Carpenter, G. Uhlenbrauck - The Journal of Infectious Diseases 2014 被引用: 329

  11. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tiziana Quirino, Giuliano Rizzardini, Jaime Andrade‐Villanueva, Juan Sierra‐Madero, Teresa Branco, Rosário Serrão, Eugénio Teófilo, Ivan Melendez-Rivera, Lizette Santiago, Carmen Zorrilla, Elena Belonosova, Oksana Chernova, Vadim Pokrovsky, Aza Rakhmanova, Olga Aleksandrovna Tsybakova, Eugene Voronin, Catherine Orrell, Tasneem Vally, Livhuwani ML. Farisani, Boitumelo Lucrecia Sebopa, Carlos Aguado Barros, Alfredo Cano Sánchez, Manuel Castaño, Vicens Falcó Ferrer, Juan González‐García, José Hernández‐Quero, Eugenia Negredo Puigmal, Marı́a Jesús Pérez-Elı́as, Daniel Podzamczer Palter, Joaquín Portilla, Pompeyo Viciana Fernández, Weerawat Manosuthi, Kiat Ruxrungtham, David H. Dockrell, Phillip Hay, Margaret Johnson, Nicola Mackie, Chloe Orkin, Steve Taylor, Laveeza Bhatti, Indira Brar, Robert Owen Brennan, Jerry Cade, Beata Casańas, Kathleen Casey, Douglas Cunningham, Edwin DeJesus, Craig Dietz, Robin Dretler, Joseph J. Eron, Franco Antoni B. Felizarta, Kenneth H. Fife, Debbie Hagins, Margaret Hoffman-Terry, Mamta K. Jain, Marc Alexander Johnson, Clifford A. Kinder, Princy Kumar, Stanley T. Lewis, Cheryl McDonald, Armando Meza, Karam Mounzer, Cheryl Newman, Olayemi Osiyemi, Ronald Poblete, Rachel M. Presti, Moti Ramgopal, Joel Rosenstock, Rafik Samuel, Uriel Sandkovsky ほか 6 名 - The Lancet HIV 2017 被引用: 118

  12. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

    著者: , , , , , , , , , , , , , , - AIDS 2007 被引用: 352

  13. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eva Poveda, Josep M. Llibre, Ferdinand Wit, Marc van der Valk, M Hillebregt, Kathy Petoumenos, M Law, D Byonanebye, J Hutchinson, Robert Zangerle, H Appoyer, J Vera, A Clarke, B Broster, L Barbour, S De Wit, M Delforge, J Begovac, Gilles Wandeler, Christoph Stephan, M Bucht, Nikoloz Chkhartishvili, Otar Chokoshvili, Antonella d’Arminio Monforte, A Rodano, A Tavelli, Iuri Fanti, Cristina Mussini, Vanni Borghi, C Pradier, Éric Fontas, K Dollet, C Caissotti, Jordi Casabona, JM Miró, Colette Smith, Fiona Lampe, M. Johnson, F Burns, C Chaloner, Antonella Castagna, Adriano Lazzarin, Alessandro Poli, Anders Sönnerborg, Karolin Falconer, Veronica Svedhem, Huldrych F. Günthard, B Ledergerber, H C Bucher, K Kusejko, J C Wasmuth, J Rockstroh, Jörg Janne Vehreschild, G Fätkenheuer, M Scherer, Nick Schulze, Bernd Franke, Lene Ryom, M Law, J. Rooney, I McNicholl, Vani Vannappagari, H Garges, Kathy Petoumenos, Gilles Wandeler, Robert Zangerle, Colette Smith, S De Wit, Jens Lundgren, Huldrych F. Günthard ほか 147 名 - Clinical Infectious Diseases 2023 被引用: 23

  14. Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

    著者: , , , , , , , , , , , , , , - Clinical Infectious Diseases 2010 被引用: 411

  15. Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony LaMarca, Trevor Hawkins - The Journal of Infectious Diseases 2012 被引用: 312

  16. A Mobile Application for Exercise Intervention in People Living with HIV

    著者: , , , , , , , , , , , , , , - Medicine & Science in Sports & Exercise 2019 被引用: 40

  17. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

    著者: , , , , , , , , , , , , , - AIDS 2024 被引用: 16

  18. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

    著者: , , , , , , , , , , , , , , , - New England Journal of Medicine 2004 被引用: 1,235

  19. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2008 被引用: 507

  20. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    著者: , , , , , , , , , , , , , , , , - The Lancet 2007 被引用: 480

  21. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adriano Lazzarin, Giovanni Landoni, Alberto Zangrillo - Clinical Immunology 2020 被引用: 312

  22. Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line

    著者: , , , , , , , , , - Blood 1998 被引用: 232

  23. Prognostic Significance of JC Virus DNA Levels in Cerebrospinal Fluid of Patients with HIV-Associated Progressive Multifocal Leukoencephalopathy

    著者: , , , , , , , , , , , , - Clinical Infectious Diseases 2005 被引用: 159

  24. Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2004 被引用: 124